Novartis’ MS drug trumps Sanofi’s Aubagio
admin 16th September 2019 Uncategorised 0The drug was able to reduce annualised MS relapse rates by 50.5% and 58.5% in the ASCLEPIOS I and II trials.
More: Novartis’ MS drug trumps Sanofi’s Aubagio
Source: News